Clinical Trials Browser

Terminated × Has results × AZD 6244 × Clear all

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Phase 2 Terminated

24 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT03095248 2025-04-22

SEL-TH-1601

Phase 2 Terminated

10 enrolled 9 charts

Ependymoma, Glioma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

NCT03833427 2024-11-07

MK-5618-001

Phase 1 Terminated

32 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT01134601 2021-12-01

A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum

Phase 1 Terminated

1 enrolled 7 charts

Gastrointestinal

Rectal Neoplasms

NCT00780676 2020-09-03

Personalized Treatment Selection for Metastatic Breast Cancer

Phase 2 Terminated

97 enrolled 7 charts

Breast Neoplasms

NCT01843062 2019-08-28

ASTRA

Phase 3 Terminated

233 enrolled 14 charts

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT01949870 2016-05-13

Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study

Phase 1 Terminated

6 enrolled 6 charts

Gastrointestinal

Biliary Tract Neoplasms

NCT01519427 2014-06-18

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Phase 2 Terminated

2 enrolled 9 charts

Melanoma

NCT01166126 2014-05-15

Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV

Phase 2 Terminated

4 enrolled 7 charts

Melanoma